|Videos|April 4, 2023

Data-Informed Insights on Second-line Treatment Selection for EGFR Exon 20-mutated mNSCLC

Author(s)Jason Porter, MD, Eric Vail, MD, Ana Velázquez Mañana, MD, MSc

Dr Porter presents recent conference data on a matching-adjusted indirect comparison of amivantamab and mobocertinib for treatment of EGFR exon 20-mutated mNSCLC, and panelists weigh in on factors influencing selection between the two regimens.

Episodes in this series

EP. 1 An Introduction to Biomarker Testing in Non-Small Cell Lung Cancer

EP. 1 An Introduction to Biomarker Testing in Non-Small Cell Lung Cancer

EP. 2 Analyzing the Relationship Between Biomarkers, Testing Rates, and Clinical Characteristics in Non-Small Cell Lung Cancer

EP. 2 Analyzing the Relationship Between Biomarkers, Testing Rates, and Clinical Characteristics in Non-Small Cell Lung Cancer

EP. 3 Available Biomarker Testing Modalities for Patients with mNSCLC

EP. 3 Available Biomarker Testing Modalities for Patients with mNSCLC

EP. 4 Clinical Experience with Coordinating Biomarker Testing for Patients with mNSCLC

EP. 4 Clinical Experience with Coordinating Biomarker Testing for Patients with mNSCLC

EP. 5 Patient Case 1: A 71-year-old Woman with Newly Diagnosed mNSCLC

EP. 5 Patient Case 1: A 71-year-old Woman with Newly Diagnosed mNSCLC

EP. 6 A Molecular Pathologist’s Insight into Institutional Best Practices for NSCLC Biomarker Testing

EP. 6 A Molecular Pathologist’s Insight into Institutional Best Practices for NSCLC Biomarker Testing

EP. 7 Challenges of Using Biomarker Testing in mNSCLC

EP. 7 Challenges of Using Biomarker Testing in mNSCLC

EP. 8 An Introduction to Three Real-World Analyses of Biomarker Testing Patterns in mNSCLC

EP. 8 An Introduction to Three Real-World Analyses of Biomarker Testing Patterns in mNSCLC

EP. 9 Overcoming Disparities in Biomarker Testing Use for mNSCLC

EP. 9 Overcoming Disparities in Biomarker Testing Use for mNSCLC

EP. 10 Patient Case 2: mNSCLC with an EGFR Exon 20 Insertion

EP. 10 Patient Case 2: mNSCLC with an EGFR Exon 20 Insertion

EP. 11 Managing Disease Progression in Patients with EGFR-mutated mNSCLC

EP. 11 Managing Disease Progression in Patients with EGFR-mutated mNSCLC

EP. 12 CHRYSALIS: Study Design and Key Results for Amivantamab in mNSCLC

EP. 12 CHRYSALIS: Study Design and Key Results for Amivantamab in mNSCLC

EP. 13 Safety and Efficacy Data for Mobocertinib in Patients with mNSCLC

EP. 13 Safety and Efficacy Data for Mobocertinib in Patients with mNSCLC

EP. 14 Data-Informed Insights on Second-line Treatment Selection for EGFR Exon 20-mutated mNSCLC

EP. 14 Data-Informed Insights on Second-line Treatment Selection for EGFR Exon 20-mutated mNSCLC

EP. 15 Patient Case 2: Second-line Treatment Selection and Adverse Event Management

EP. 15 Patient Case 2: Second-line Treatment Selection and Adverse Event Management

EP. 16 Insights into Third-Line Treatment Selection for Patients with EGFR Exon 20-mutated mNSCLC

EP. 16 Insights into Third-Line Treatment Selection for Patients with EGFR Exon 20-mutated mNSCLC

EP. 17 Key Takeaways Regarding Biomarker Testing for mNSCLC

EP. 17 Key Takeaways Regarding Biomarker Testing for mNSCLC

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

2 experts in this video

The Evolving MPN Landscape: Future Therapeutic Directions and Addressing Unmet Needs in Myelofibrosis and Polycythemia Vera

ByPankit Vachhani, MD,Raajit Rampal, MD, PhD

July 7th 2025

2 experts in this video

Emerging Treatment Paradigms: Rusfertide’s VERIFY Trial and Molecular Response-Guided Therapy in Advanced PV

ByPankit Vachhani, MD,Raajit Rampal, MD, PhD

July 7th 2025

2 experts in this video

Interferon Therapy Evolution: Clinical Applications and Paradigm Shifts in Polycythemia Vera Management

ByPankit Vachhani, MD,Raajit Rampal, MD, PhD

June 27th 2025

2 experts in this video

Management Strategies for Hydroxyurea-Resistant PV: Treatment Optimization and Evidence-Based Second-Line Selection

ByPankit Vachhani, MD,Raajit Rampal, MD, PhD

June 27th 2025

2 experts in this video

Response Assessment: Monitoring Parameters and Molecular Testing Integration

ByPankit Vachhani, MD,Raajit Rampal, MD, PhD

June 19th 2025

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Kamel Abou Hussein, MD; Kate Baxstrom, MD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Ajit K. Bisen, MD, MBA; Virginia Kaklamani, MD, DSc

Satellite Symposia at the Annual Radiation Oncology Meeting

In-Person + Virtual Event

Satellite Symposia at the Annual Radiation Oncology Meeting

September 26-28, 2026

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Virginia Kaklamani, MD, DSc; Denise Yardley, MD, GCRA

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Kamel Abou Hussein, MD; Yan Ji, MD, PhD

North Carolina Oncology Association

North Carolina Oncology Association

2 Sessions are Available!

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Kamel Abou Hussein, MD; Kit Y Lu, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Kamel Abou Hussein, MD; Sushil Bhardwaj, MD, FACP

Washington State Medical Oncology Society

Washington State Medical Oncology Society

2 Sessions are Available!

Missouri Oncology Society

Missouri Oncology Society

2 Sessions are Available!

New Mexico Society of Clinical Oncology

New Mexico Society of Clinical Oncology

3 Sessions are Available!

Louisiana Oncology Society

Louisiana Oncology Society

3 Sessions are Available!

Nevada Oncology Society

Nevada Oncology Society

2 Sessions are Available!

Wyoming State Oncology Society

Wyoming State Oncology Society

2 Sessions are Available!

Montana State Oncology Society

Montana State Oncology Society

2 Sessions are Available!

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

24th Annual School of Breast Oncology

In-Person Event

24th Annual School of Breast Oncology

November 5-7, 2026

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Tiffany A. Traina, MD, FASCO; Kevin Kalinsky, MD MS, FASCO; Mark E. Robson, MD, FASCO; Rebecca Shatsky, MD

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; Cynthia X. Ma, MD, PhD

Module 4: Breast Surgery (2025)

Module 4: Breast Surgery (2025)

Eleftherios (Terry) Mamounas, MD, MPH, FACS; Michael Alvarado, MD, MS; Puneet Singh, MD, MS, FACS, FSSO, CMQ

Module 5: Breast Radiation Therapy (2025)

Module 5: Breast Radiation Therapy (2025)

Douglas W. Arthur, MD, FABS, FASTRO; Eleanor E. Harris, MD, FASTRO; Kathleen Horst, MD

Module 3: Pathology And Biomarkers (2025)

Module 3: Pathology And Biomarkers (2025)

Joyce O’Shaughnessy, MD; Sunil S. Badve, MD, FRCPath; Claudine Isaacs, MD; Michael F. Press, MD, PhD

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; N. Lynn Henry, MD, PhD, FASCO; Kevin Kalinsky, MD, MS; Joseph A. Sparano, MD; Sara Tolaney, MD, MPH

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Joyce O’Shaughnessy, MD; Carol Fabian, MD; Rachel Freedman, MD, MPH; Anne Grabenstetter, MD; Claudine Isaacs, MD; Pedram Razavi, MD, PhD

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

William J. Gradishar, MD, FASCO, FACP; Ting Bao, MD, MS; Jennifer A. Ligibel, MD; Filipa Lynce, MD; Ruth O’Regan, MD, MSc

Module 2: Breast Imaging (2025)

Module 2: Breast Imaging (2025)

Joyce O’Shaughnessy, MD; Connie Lehman, MD, PhD, FACR; David M. Schuster, MD, FACR

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Joyce O’Shaughnessy, MD; Michelle Melisko, MD; Beverly Moy, MD, MPH

Module 9: Toxicity Management And Survivorship Considerations (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

Joyce O’Shaughnessy, MD; Laura Huppert, MD; Michelle Melisko, MD; Michelle Mollica, PhD, MPH, RN, OCN; Ann H. Partridge, MD, MPH

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Adam Brufsky, MD, PhD

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Sherene Loi, MMBS (Hons), FRACP, PhD, FAHMS

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC

AUA/SUO Issue 2026 Update to Non–Muscle-Invasive Bladder Cancer Guideline

Dr Pant Discusses Next Steps in Daraxonrasib Development for Pancreatic Cancer

FDA Approves Camizestrant Plus CDK4/6 Inhibitor for ESR1-Mutant Breast Cancer

Why Do Asian American Women Have Better Breast Cancer Survival?